<DOC>
	<DOCNO>NCT02209753</DOCNO>
	<brief_summary>The clinical objective study determine effect BIRB 796 BS pharmacodynamic marker psoriasis measure efficacy , determine population pharmacokinetics BIRB 796 BS determine safety BIRB 796 BS 4 week treatment patient moderate severe plaque-type psoriasis .</brief_summary>
	<brief_title>BIRB 796 BS Versus Placebo Patients With Moderate Severs Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Patients stable moderate severe plaquetype psoriasis involve ≥5 % body surface area History plaque psoriasis minimum 6 month prior screen Age 18 75 Males female , female must nonchildbearing potential ( 6 month postmenopausal , surgically sterilize ) use approve form birth control ( oral contraceptive , Norplant® , DepoProvera® , intrauterine device ( IUD ) , doublebarrier ) negative serum pregnancy test upon screen ( Visit 1 ) negative urine test prior randomization ( Visit 2 ) trial Give inform consent sign approve consent form prior study procedure , include washout prohibit medication Primary guttate , erythrodermic , pustular psoriasis Psoriasis fail improve significantly systemic treatment cyclosporine methotrexate . Patients resistant one , document response another may include approval medical monitor . Treatment failure include failure improve full course treatment unable complete due adverse event , intolerance treatment administrative reason Patients experience treatment failure TNFblocking agent . Treatment failure define achieve least 40 % reduction PASI score TNFblocking agent discontinue due lack efficacy Patients unable wash current psoriasis treatment ( systemic , topical phototherapy ) except emollient shampoos prior begin trial medication Patients take following medication know elevate liver enzyme take medication stable dose least 1 month ( 3 month diclofenac ) without change liver function test ( LFTs ) prior randomization ( Visit 2 ) : estrogen , oral contraceptive , selective serotonin reuptake inhibitor ( SSRIs ) , nonsteroidal antiinflammatory drug ( NSAIDs ) , acetominophen ≤3 g/day , aspirin , vitamin supplement ( recommend daily allowance dos ) . Patients take dos acetaminophen great three gram per day exclude . Any medication know elevate hepatic enzyme list exclude Patients use medication list protocol , without appropriate washout period Patients clinically significant abnormal baseline hematology , blood chemistry urinalysis abnormality define disease list exclusion criterion . All patient serum glutamate oxaloacetate transaminase , serum glutamate pyruvate transaminase , alkaline phosphatase great 1.5 x upper limit normal ( ULN ) total bilirubin great 1.0 x ULN exclude regardless clinical condition . Patients serum creatinine , white blood cell ( WBC ) count , amylase , lipase , prothrombin time ( PT ) , partial thromboplastin time ( PTT ) , Ddimer , fibrin degradation product ( FDP ) great 1.5 x ULN , blood smear poikilocytes schistocytes great 1.0 x ULN also exclude . Patients hemoglobinuria proteinuria great 1+ exclude . Hemoglobinuria must confirm hematuria find red blood cell ( RBC ) microscopic examination . Hematuria menstruate female require exclusion must repeat menses clear prior entry . Repeat laboratory testing allow screen prior exclude patient , avoid exclude patient transient erroneous abnormal laboratory value Any clinically significant psychiatric illness may interfere patient 's participation trial ability interpret trial result History cardiovascular , renal , neurologic , liver , immunologic endocrine dysfunction clinically significant . A clinically significant disease define one opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study Patients history heart failure , patient recent history ( i.e. , 1 year less ) myocardial infarction patient arrhythmia require drug therapy Any ECG value outside reference range clinical relevance include , limited , QTcB &gt; 480 m , PR interval &gt; 240 m , QRS interval &gt; 110 ms History malignancy past 5 year except treat cutaneous squamous cell basal cell carcinoma Any active immunodeficiency active infection , serious infection ( require hospitalization IV/intramuscular antibiotic ) past 3 month prior screen . Patients test positive human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C exclude History prior tuberculosis infection active tuberculosis , patient must negative skin test chest xray within past 6 month prior screen ( Visit 1 ) History drug alcohol abuse within past 2 year , active drug alcohol abuse , patient consume three alcoholic drink per day Patients take investigational drug within one month ( 30 day ) six half life ( whichever great ) prior screen ( Visit 1 ) . Patients treat investigational antibody biological agent within past 3 month exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>